Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Olaparib

Aliases
AZD2281, AZD 2281, AZD-2281, KU-0059436, Lynparza (15 other aliases)
Name
Olaparib
Target
PARP
FDA Approved
Yes
Ema approved
Status
0

173 clinical trials

1 organization

1 drug

4 abstracts

339 indications

1 document

Indication
Breast Cancer
Indication
Solid Tumours
Indication
Breast Neoplasms
Indication
Ovarian Cancer
Indication
Metastatic Castration-Resistant Prostate Cancer
Indication
Lung Cancer
Indication
Cancer
Indication
Ovarian
Indication
Breast
Indication
small cell lung cancer
Indication
Triple Negative Breast Cancer
Indication
Solid Tumors
Indication
Endometrial Neoplasms
Indication
Prostate Cancer
Indication
Advanced Solid Tumor
Indication
Metastatic Solid Tumor
Indication
cancer
Indication
Squamous Cell
Indication
Stomach Cancer
Indication
Castration-Resistant
Indication
Non-Small Cell Lung
Indication
Healthy Participants
Indication
Ovarian Neoplasm
Indication
Pancreatic Cancer
Indication
Pancreatic Neoplasms
Indication
Castrate-Resistant Prostate Cancer
Indication
Castration-Resistant Prostate Cancer
Indication
Triple-negative Breast Cancer
Indication
Triple-Negative Breast Cancer
Indication
Breast Tumor
Indication
Muscle Invasive Bladder Cancer
Indication
Non-small-cell Lung
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
Advanced Solid Tumours
Indication
Small Cell Lung Cancer
Indication
Germline BRCA1/2 Mutations
Indication
Pancreatic Adenocarcinoma
Indication
Cancer of Unknown Primary Site
Indication
Fallopian tube cancer
Indication
Peritoneal Neoplasms
Indication
Metastatic Breast Cancer
Indication
BRCA1/2 Mutations
Indication
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Indication
Pancreatic Ductal Adenocarcinoma
Indication
Homologous Recombination Deficiency
Indication
Head and Neck Cancer
Indication
Bile Duct Cancer
Indication
Chemotherapy Effect
Indication
Malignant Neoplasm
Indication
Non-Hodgkin Lymphoma
Indication
Stage IV Non-Hodgkin Lymphoma
Indication
Histiocytic Sarcoma
Indication
Juvenile Xanthogranuloma
Indication
Langerhans Cell Histiocytosis
Indication
Malignant Glioma
Indication
Recurrent Childhood Rhabdomyosarcoma
Indication
Ependymoma
Indication
Ewing Sarcoma
Indication
Recurrent Glioma
Indication
Hepatoblastoma
Indication
Recurrent Langerhans Cell Histiocytosis
Indication
Recurrent Malignant Germ Cell Tumor
Indication
Recurrent Malignant Solid Neoplasm
Indication
Medulloblastoma
Indication
Neuroblastoma
Indication
Osteosarcoma
Indication
Peripheral Primitive Neuroectodermal Tumor
Indication
Recurrent Primary Central Nervous System Neoplasm
Indication
Recurrent rhabdoid tumor
Indication
Soft Tissue Sarcoma
Indication
Glioma
Indication
Malignant Germ Cell Tumor
Indication
Malignant Solid Neoplasm
Indication
Refractory Non-Hodgkin Lymphoma
Indication
Refractory Primary Central Nervous System Neoplasm
Indication
Rhabdoid Tumor
Indication
Rhabdomyosarcoma
Indication
Soft Tissue Sarcoma AJCC v7
Indication
Osteosarcoma AJCC v7
Indication
Stage IV Soft Tissue Sarcoma AJCC v7
Indication
Wilms tumor
Indication
Digestive Organ Neoplasms
Indication
Malignant Neoplasms of Female Genital Organs
Indication
Malignant Neoplasms of Male Genital Organs
Indication
Malignant Gliomas
Indication
Radiotherapy
Indication
PARP inhibitor
Indication
Glioblastoma
Indication
Thyroid and Other Endocrine Glands Malignant Neoplasms
Indication
BRCA1 Mutation
Indication
BRCA2 mutation
Indication
BRCA Mutation
Indication
BRCA-Associated Breast Carcinoma
Indication
Endometrial Cancer
Indication
Squamous Cell Carcinoma of Head and Neck
Indication
Small Cell Lung Carcinoma
Indication
Immunotherapy
Indication
Metastatic Lung Non-Small Cell Carcinoma
Indication
Triple-Negative Breast Carcinoma
Indication
Stage III Breast Cancer
Indication
Stage III Lung Non-Small Cell Cancer
Indication
Stage III Lung Small Cell Carcinoma AJCC v7
Indication
Stage III Pancreatic Cancer
Indication
Stage IIIA Breast Cancer
Indication
Stage IIIA Lung Non-Small Cell Cancer
Indication
Lung Small Cell Carcinoma AJCC v7
Indication
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Indication
Stage IIIB Small Cell Lung Carcinoma AJCC v7
Indication
Breast cancer
Indication
Stage IV Lung Non-Small Cell Cancer AJCC v7
Indication
Small Cell Lung Carcinoma, Stage IV (AJCC v7)
Indication
Stage IV Pancreatic Cancer
Indication
Unresectable Pancreatic Carcinoma
Indication
Prostate adenocarcinoma with neuroendocrine differentiation
Indication
Castration-Resistant Prostate Carcinoma
Indication
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation
Indication
Prostate Adenocarcinoma With Neuroendocrine Differentiation
Indication
Prostate Adenocarcinoma
Indication
Ovarian High Grade Serous Adenocarcinoma
Indication
Platinum-Resistant Ovarian Carcinoma
Indication
Breast Cancer, Stage IV
Indication
Breast Carcinoma
Indication
Pancreatic Carcinoma
Indication
Advanced Sarcoma
Indication
Recurrent Ovarian Carcinoma
Indication
Stage III Ovarian Cancer AJCC v8
Indication
Brain Metastases
Indication
Adult
Indication
Stage IV Ovarian Cancer
Indication
Triple-Negative
Indication
Breast Neoplasm Malignant Female
Indication
Radiotherapy Side Effect
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Metastatic Head and Neck Squamous Cell Carcinoma
Indication
Recurrent Diffuse Large B-Cell Lymphoma
Indication
Recurrent T-Cell Non-Hodgkin Lymphoma
Indication
Diffuse Large B-Cell Lymphoma
Indication
lymphoma
Indication
Non-Hodgkin
Indication
Multiple Myeloma
Indication
Metastatic Castrate Resistant Prostate Cancer
Indication
BARD1
Indication
BRCA1
Indication
BRCA2
Indication
BRIP1
Indication
CHEK1
Indication
Cholangiocarcinoma
Indication
High-Risk Cancer
Indication
Pancreatic Acinar Cell Carcinoma
Indication
Pancreatic Adenosquamous Carcinoma
Indication
Pancreatic Squamous Cell Carcinoma
Indication
Endometrial Carcinosarcoma
Indication
Fallopian Tube Carcinoma
Indication
Platinum-Refractory Ovarian Carcinoma
Indication
Primary Peritoneal Carcinoma
Indication
Endometrioid Adenocarcinoma
Indication
High-Grade Serous Adenocarcinoma
Indication
Ovarian Endometrioid Adenocarcinoma
Indication
Platinum-Resistant Fallopian Tube Carcinoma
Indication
Recurrent primary peritoneal high-grade serous adenocarcinoma
Indication
Locally Advanced Breast Cancer
Indication
Fanconi anemia
Indication
PALB2
Indication
RAD51B
Indication
RAD51C
Indication
RAD51D
Indication
RAD54L Mutations
Indication
Bile Duct Adenocarcinoma
Indication
Fanconi Anemia Complementation Group Gene Mutation
Indication
PTEN Gene Deletion
Indication
Castration-resistant Prostate Cancer
Indication
Recurrent Disease
Indication
lung cancer
Indication
Extensive-stage Small-cell Lung Cancer
Indication
Hodgkin's Lymphoma
Indication
Refractory T-Cell Non-Hodgkin Lymphoma
Indication
Colon Cancer
Indication
Pancreatic adenocarcinoma
Indication
Leiomyosarcoma
Indication
Childhood Non-Hodgkin Lymphoma
Indication
Low-grade glioma
Indication
Recurrent Childhood Central Nervous System Neoplasm
Indication
Childhood Ependymoma
Indication
Germ Cell Tumor
Indication
Recurrent Childhood Soft Tissue Sarcoma
Indication
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Indication
Childhood Malignant Germ Cell Tumor
Indication
Refractory Soft Tissue Sarcoma
Indication
Renal Cell Carcinoma
Indication
Locally Advanced Malignant Solid Neoplasm
Indication
Metastatic Malignant Solid Neoplasm
Indication
Metastatic Urothelial Carcinoma
Indication
Gastric Esophageal Cancer
Indication
Ovarian Carcinoma
Indication
BRCA1 Gene Mutation
Indication
High Grade Fallopian Tube Serous Adenocarcinoma
Indication
Ovarian Serous Adenocarcinoma
Indication
Primary Peritoneal High Grade Serous Adenocarcinoma
Indication
Fallopian Tube Cancer
Indication
Stage III Primary Peritoneal Cancer AJCC v8
Indication
Stage IIIA Primary Peritoneal Cancer AJCC v8
Indication
Fallopian Tube Cancer, Stage IIIA1 AJCC v8
Indication
Stage IIIA1 Ovarian Cancer AJCC v8
Indication
Stage IIIA2 Fallopian Tube Cancer AJCC v8
Indication
Ovarian Cancer, Stage IIIB (AJCC v8)
Indication
Primary Peritoneal Cancer
Indication
Fallopian Tube Cancer, Stage IV, AJCC v8
Indication
Primary Peritoneal Cancer (Stage IV)
Indication
Stage IV Fallopian Tube Cancer AJCC v8
Indication
Stage IV Ovarian Cancer AJCC v8
Indication
Stage IVA Primary Peritoneal Cancer AJCC v8
Indication
Ovarian Cancer Stage IVB AJCC v8
Indication
Stage IVB Primary Peritoneal Cancer AJCC v8
Indication
Renal Cell Cancer
Indication
Stage IV Renal Cell Cancer
Indication
Breast Cancer Metastatic
Indication
HER2-low breast carcinoma
Indication
Endometrioid Tumor
Indication
Fallopian Tube High Grade Serous Adenocarcinoma
Indication
Ovarian Endometrioid Tumor
Indication
Platinum-Sensitive Ovarian Carcinoma
Indication
Platinum-Sensitive Primary Peritoneal Carcinoma
Indication
Recurrent Fallopian Tube Carcinoma
Indication
Recurrent Primary Peritoneal Carcinoma
Indication
Recurrent cholangiocarcinoma
Indication
Grade 2 Glioma
Indication
Grade 3 Glioma
Indication
Melanoma
Indication
Mucosal melanoma
Indication
Uveal melanoma
Indication
Prostate
Indication
Colorectal Cancer
Indication
fallopian tube carcinoma
Indication
Endometrioid ovarian adenocarcinoma
Indication
Ovarian Serous Surface Papillary Adenocarcinoma
Indication
Primary Peritoneal Serous Adenocarcinoma
Indication
Uterine Corpus Leiomyosarcoma
Indication
Uterine Leiomyosarcoma
Indication
Uterine Corpus Leiomyosarcoma AJCC v8
Indication
Neoadjuvant Treatment
Indication
Surgical Procedures, Elective
Indication
Breast Cancer, Anatomic Stage IIIA AJCC v8
Indication
Breast Cancer, Anatomic Stage IIIB AJCC v8
Indication
BRCA1 gene mutation
Indication
Germline BRCA2 Gene Mutation
Indication
HER2/Neu Negative
Indication
Breast Cancer, Prognostic Stage III AJCC v8
Indication
Stage IIIB Breast Cancer
Indication
Stage IV Breast Cancer AJCC v8
Indication
Epithelial Ovarian Cancer
Indication
Thyroid Cancer
Indication
CHEK2 mutation
Indication
ATM Gene Mutation
Indication
PALB2 Gene Mutation
Indication
RAD51 Gene Mutation
Indication
BRIP1 Gene Mutation
Indication
Nijmegen Breakage Syndrome
Indication
Primary Peritoneal Endometrioid Adenocarcinoma
Indication
Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
Indication
Recurrent Prostate Carcinoma
Indication
Gastric Adenocarcinoma
Indication
Ocular melanoma
Indication
Acute Myeloid Leukemia
Indication
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Indication
Recurrent Acute Myeloid Leukemia
Indication
Myelodysplastic Syndrome
Indication
Gastroenteropancreatic Tumors
Indication
Neuroendocrine Tumors
Indication
Bladder Cancer
Indication
Genitourinary System Carcinoma
Indication
Bladder Cancer Stage III AJCC v8
Indication
Stage IV Bladder Cancer
Indication
Malignant Neoplasm of Female Reproductive System
Indication
Recurrent Malignant Female Reproductive System Neoplasm
Indication
Breast Cancer Triple Negative
Indication
DNA Damage Repair Deficiency
Indication
Prostate Cancer Metastatic Castration-Resistant
Indication
Abnormal DNA Repair
Indication
Mucinous Adenocarcinoma of the Fallopian Tube
Indication
Ovarian Seromucinous Carcinoma
Indication
Clear Cell Adenocarcinoma
Indication
Recurrent Fallopian Tube Mucinous Adenocarcinoma
Indication
Fallopian Tube Transitional Cell Carcinoma
Indication
Recurrent fallopian tube undifferentiated carcinoma
Indication
Low Grade Serous Adenocarcinoma
Indication
Ovarian Clear Cell Adenocarcinoma
Indication
Low Grade Serous Ovarian Adenocarcinoma
Indication
Ovarian Mucinous Adenocarcinoma
Indication
Recurrent Ovarian Seromucinous Carcinoma
Indication
Recurrent Ovarian Transitional Cell Carcinoma
Indication
Primary Peritoneal Clear Cell Adenocarcinoma
Indication
Primary Peritoneal Transitional Cell Carcinoma
Indication
Primary Peritoneal Undifferentiated Carcinoma
Indication
Clear Cell Adenocarcinoma of the Fallopian Tube
Indication
Fallopian tube high-grade serous adenocarcinoma
Indication
Refractory Fallopian Tube Mucinous Adenocarcinoma
Indication
Refractory Fallopian Tube Undifferentiated Carcinoma
Indication
Low Grade Fallopian Tube Serous Adenocarcinoma
Indication
High Grade Serous Ovarian Adenocarcinoma
Indication
Ovarian Transitional Cell Carcinoma
Indication
Refractory Ovarian Undifferentiated Carcinoma
Indication
High Grade Serous Adenocarcinoma
Indication
Peritoneal Undifferentiated Carcinoma
Indication
Laryngeal Cancer
Indication
Laryngeal Cancer Stage III
Indication
Head and Neck Neoplasms
Indication
Relapsed Ovarian Cancer
Indication
High-grade serous carcinoma
Indication
Clinical Stage III Cutaneous Melanoma AJCC v8
Indication
Stage IV Cutaneous Melanoma
Indication
Metastatic Melanoma
Indication
Castrate-Sensitive Prostate Cancer
Indication
Oligometastatic Disease
Indication
HRD Positive Advanced Ovarian Cancer
Indication
Tumor
Indication
Neoplasia
Indication
Cutaneous Melanoma
Indication
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Indication
Stage IIIC Cutaneous Melanoma AJCC v8
Indication
Stage IIID Cutaneous Melanoma AJCC v8
Indication
Stage III Lung Cancer AJCC v8
Indication
Stage III Renal Cell Cancer AJCC v8
Indication
Stage IIIA Lung Cancer
Indication
Stage IIIB Lung Cancer
Indication
Stage IV Lung Cancer
Indication
Stage IV Renal Cell Cancer AJCC v8
Indication
Lung Cancer Stage IVA AJCC v8
Indication
melanoma
Indication
Pediatric Cancer
Indication
Extensive-stage small cell lung cancer
Indication
Mesothelioma
Indication
HRD
Indication
Recurrent Ovarian Cancer
Indication
Breast Inflammatory Carcinoma
Indication
Extensive-Stage Small Cell Lung Cancer
Drug
Olaparib
Indication
Choroid Plexus Carcinoma
Indication
Lymphoma
Indication
NSCLC
Indication
Gastric Cancer
Clinical trial
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2020-03-27
Clinical trial
A Phase II, Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients With Advanced BRCA1- or BRCA2-associated Breast Cancer.
Status: Completed, Estimated PCD: 2009-02-27
Clinical trial
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Status: Active (not recruiting), Estimated PCD: 2023-09-18
Clinical trial
A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2021-09-17
Clinical trial
An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) (KEYLYNK-009)
Status: Active (not recruiting), Estimated PCD: 2022-12-15
Clinical trial
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours
Status: Recruiting, Estimated PCD: 2025-12-30
Clinical trial
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).
Status: Active (not recruiting), Estimated PCD: 2020-11-13
Clinical trial
A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
Status: Active (not recruiting), Estimated PCD: 2025-07-24
Clinical trial
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Status: Active (not recruiting), Estimated PCD: 2025-03-05
Clinical trial
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
Status: Active (not recruiting), Estimated PCD: 2024-09-04
Clinical trial
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Status: Completed, Estimated PCD: 2022-03-14
Clinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-14
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2023-09-21
Clinical trial
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Status: Completed, Estimated PCD: 2016-04-04
Clinical trial
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Status: , Estimated PCD: 2024-12-10
Clinical trial
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status: Not yet recruiting, Estimated PCD: 2028-03-31
Clinical trial
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed Following Standard of Care Platinum-Based Chemotherapy With Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)
Status: Active (not recruiting), Estimated PCD: 2021-01-11
Clinical trial
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Status: Recruiting, Estimated PCD: 2028-03-29
Clinical trial
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2023-04-21
Clinical trial
An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-01-03
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
Status: Active (not recruiting), Estimated PCD: 2026-07-06
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)
Status: Recruiting, Estimated PCD: 2024-07-02
Clinical trial
A Randomized, Open-Label, 2-formulation, Single-Dose, 2-Period Crossover Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects
Status: Completed, Estimated PCD: 2022-08-21
Clinical trial
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Status: Active (not recruiting), Estimated PCD: 2028-05-30
Clinical trial
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Status: Recruiting, Estimated PCD: 2027-10-22
Clinical trial
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Status: Active (not recruiting), Estimated PCD: 2020-03-18
Clinical trial
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
Status: Completed, Estimated PCD: 2021-09-08
Clinical trial
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-13
Clinical trial
A Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2019-09-13
Clinical trial
A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
Status: Completed, Estimated PCD: 2014-04-08
Clinical trial
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy
Status: Completed, Estimated PCD: 2020-10-02
Clinical trial
A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Status: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel
Status: Completed, Estimated PCD: 2017-09-22
Clinical trial
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Status: Completed, Estimated PCD: 2019-01-15
Clinical trial
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation
Status: Completed, Estimated PCD: 2022-09-30
Clinical trial
A Randomized, Open Label, Multi-centre, Two-treatment, Two-period, Two-sequence, Two-stage, Multiple Dose, Steady-state, Crossover, Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer Under Fasting Condition
Status: Completed, Estimated PCD: 2022-10-20
Clinical trial
A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination With Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status: Terminated, Estimated PCD: 2022-05-24
Clinical trial
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2023-02-14
Clinical trial
Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance
Status: Completed, Estimated PCD: 2023-02-17
Clinical trial
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Clinical trial
A Pan-European Non-interventional, Retrospective Observational Cohort Study of Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Treated With Olaparib Tablets in the First-line Maintenance Setting
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.
Status: Completed, Estimated PCD: 2021-10-08
Clinical trial
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2025-05-01
Abstract
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,
Clinical trial
A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)
Status: Active (not recruiting), Estimated PCD: 2020-06-01
Clinical trial
DDR-Umbrella Study of DDR (DNA-Damage Response) Targeting Agents in Advanced Biliary Tract Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2020-12-02
Clinical trial
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance
Status: Active (not recruiting), Estimated PCD: 2026-08-30
Clinical trial
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
Status: Recruiting, Estimated PCD: 2024-09-13
Clinical trial
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Multicenter Double Blind Randomized Phase II Trial of Olaparib vs Placebo as Maintenance Therapy in Platinum-sensitive Advanced Endometrial Carcinoma
Status: Active (not recruiting), Estimated PCD: 2023-05-22
Clinical trial
A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Status: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
Olaparib Maintenance Therapy in Patients With Metastatic Breast Cancer Following DNA-damaging Based Chemotherapy
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment
Status: Active (not recruiting), Estimated PCD: 2027-08-10
Clinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2022-06-22
Clinical trial
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-03-14
Clinical trial
A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Olaparib Plus Low-Dose Alpelisib for Breast Cancer: A ComboMATCH Treatment Trial
Status: Withdrawn, Estimated PCD: 2025-04-30
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)
Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Status: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease
Status: Completed, Estimated PCD: 2020-02-17
Clinical trial
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Single-Arm, Phase 2 Trial
Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors
Status: , Estimated PCD: 2025-03-01
Clinical trial
A Phase II, Open-Label, Study of Olaparib in Combination With Either Durvalumab (MEDI4736), Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE)
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)
Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
A Phase II Study of Olaparib in Patients With Advanced Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Status: Recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy
Status: Withdrawn, Estimated PCD: 2023-03-17
Clinical trial
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
Status: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Phase I Study of Low-Dose Radiotherapy Plus Chemotherapy and Sugemalimab and Olaparib for First-Line Treatment of SLFN-11 Positive Extensive Stage Small Cell Lung Cancer
Status: Recruiting, Estimated PCD: 2026-06-20
Clinical trial
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Status: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Study of Induction SBRT and Olaparib Followed by Combination Pembrolizumab/Olaparib in Gastric and Gastroesophageal Junction (GEJ) Cancers
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-22
Clinical trial
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance
Status: Not yet recruiting, Estimated PCD: 2025-08-30
Clinical trial
A Non-randomized Prospective Phase II Study of Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Non-Randomized, Open-Label, Prospective Phase II Trial to Better Characterize the Status of HRD Leading to a Benefit From Olaparib in Combination With Bevacizumab in Patients With Advanced FIGO Stage III-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First-Line Treatment
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
Status: Recruiting, Estimated PCD: 2026-08-08
Clinical trial
A Phase 1 Study of Olaparib in Combination With Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2021-07-31
Clinical trial
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Pilot Trial of Olaparib in Patients With Unresectable or Metastatic Melanoma With Mutations in BRCA1/2 Genes
Status: Withdrawn, Estimated PCD: 2026-05-01
Clinical trial
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Status: Active (not recruiting), Estimated PCD: 2023-05-24
Clinical trial
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase I Sequential Trial of Agents Against DNA Repair (STAR)
Status: Active (not recruiting), Estimated PCD: 2023-02-22
Clinical trial
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2018-10-31
Clinical trial
A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
Status: , Estimated PCD: 2030-03-09
Clinical trial
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Status: Recruiting, Estimated PCD: 2027-03-15
Clinical trial
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Status: Active (not recruiting), Estimated PCD: 2022-07-07
Clinical trial
Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib
Status: Active (not recruiting), Estimated PCD: 2023-11-15
Clinical trial
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot Study
Status: Active (not recruiting), Estimated PCD: 2024-06-06
Clinical trial
Phase II Study of Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
Phase 2 Study of Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Status: Recruiting, Estimated PCD: 2028-04-01
Clinical trial
Phase II Study of Pembrolizumab in Combination With Radiation With or Without Olaparib in Localized High-risk Prostate Cancer
Status: Recruiting, Estimated PCD: 2026-07-02
Clinical trial
A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Status: Recruiting, Estimated PCD: 2024-12-09
Clinical trial
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Pilot Study of Neoadjuvant Response-Adapted Chemotherapy With Pembrolizumab in Patients With Stage 2 and 3 Triple Negative Breast Cancer to Determine Early PET and Biomarker Dynamics
Status: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Status: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent Osteosarcoma
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Status: Recruiting, Estimated PCD: 2024-08-21
Clinical trial
A Randomized Phase II Study of Temozolomide Monotherapy or in Combination With Olaparib in Patients With METHYLATED 06-Methylguanine-DNA Methyltransferase (MGMT) Pre-Treated Triple Negative Breast Cancer (TNBC)
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Clinical trial
Randomized Open-labeled Phase 2 Study of Maintenance Olaparib With or Without Durvalumab for DDR Gene Mutated Advanced Biliary Tract Cancer Following Platinum-based Chemotherapy
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Status: Active (not recruiting), Estimated PCD: 2026-12-16
Clinical trial
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
Status: Recruiting, Estimated PCD: 2028-10-01
Clinical trial
Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Status: Active (not recruiting), Estimated PCD: 2020-01-14
Clinical trial
A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast Study)
Status: Completed, Estimated PCD: 2022-12-15
Clinical trial
A Phase II Open-Label Study for the Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation in BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a Homologous Recombination Deficiency
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Status: Active (not recruiting), Estimated PCD: 2020-08-01
Clinical trial
Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study
Status: Completed, Estimated PCD: 2022-07-18
Clinical trial
Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients
Status: Active (not recruiting), Estimated PCD: 2023-07-12
Clinical trial
A Pilot Study to Evaluate the Efficacy and Safety of Preoperative Olaparib Monotherapy and Preoperative Olaparib Plus Pembrolizumab Combination Therapy in Patients With HRD-Positive Stage III or IV Advanced Epithelial Ovarian/Fallopian Tube/Primary Peritoneal Cancer
Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer
Status: Completed, Estimated PCD: 2021-03-05
Clinical trial
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Status: , Estimated PCD: 2024-11-30
Clinical trial
Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With Platinum-resistant Ovarian Cancer
Status: Completed, Estimated PCD: 2021-03-12
Clinical trial
Observational Retrospective Cohort Study in Patients With Relapsed Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated With Olaparib Following Response to Platinium-based Chemotherapy
Status: Completed, Estimated PCD: 2020-02-11
Clinical trial
A Multi-Center Phase II Study Testing the Activity of Olaparib and AZD6738 (ATR Inhibitor) in Metastatic Castration-Resistant Prostate Cancer
Status: Active (not recruiting), Estimated PCD: 2023-01-26
Clinical trial
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in Triple-negative Metastatic Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I Trial of the Combination of Olaparib and Navitoclax in Women With High Grade Serous Epithelial Ovarian Cancer and Triple Negative Breast Cancer
Status: Recruiting, Estimated PCD: 2024-04-28
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
WIndow of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in REnal Cell Cancer
Status: Recruiting, Estimated PCD: 2025-11-30
Clinical trial
Arterial Hypertension With PARP Inhibitors in Cancer Patients: an Observational and Retrospective Study Using the WHO Pharmacovigilance Database (ArteRIB)
Status: Completed, Estimated PCD: 2021-05-09
Clinical trial
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, ADT, Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON): A Phase II, Single Arm, Single Institution Study
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors
Status: Terminated, Estimated PCD: 2024-05-22
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
Status: Terminated, Estimated PCD: 2023-05-31
Clinical trial
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase I/Ib Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination With Olaparib in Patients With BRCA1/2-Mutant Tumors
Status: Withdrawn, Estimated PCD: 2026-12-06
Clinical trial
A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
Status: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Phase II Trial of Olaparib in Homologous Recombination Deficient (HRD) Malignant Mesothelioma
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Phase II Trial of Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase II, Single-arm Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients With Advanced Cholangiocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair
Status: Terminated, Estimated PCD: 2023-07-06
Clinical trial
A Phase II Multicentric Study of Olaparib in PALB2-related Advanced Pancreatic Cancer (PALBOLA)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Sequential Maintenance With Thoracic Radiotherapy and Durvalumab (MEDI4736) Monotherapy or Durvalumab (MEDI 4736) Combinations (Tremelimumab or Olaparib) in Patients With Extensive Stage-Small Cell Lung Cancer After First Line Platinum Based Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2023-06-01
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10431
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20266
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20248
Document
DailyMed Label: Lynparza
Organization
AstraZeneca Pharmaceuticals LP